Senores Pharmaceuticals Limited has filed its quarterly monitoring agency report for Q3FY26, providing a comprehensive update on the utilization of proceeds from its ₹500.00 crore Initial Public Offering. The report, prepared by CARE Ratings Limited as the monitoring agency, was reviewed by the Audit Committee and approved by the Board of Directors on January 20, 2026.

IPO Proceeds Utilization Overview

The monitoring report reveals that as of December 31, 2025, the company has utilized ₹362.12 crore out of the total ₹500.00 crore raised through the IPO, leaving ₹137.88 crore unutilized. The IPO was conducted from December 20, 2024, to December 24, 2024, comprising entirely of fresh equity shares.

Objective-wise Fund Deployment

The company's IPO proceeds were allocated across seven specific objectives, with varying levels of completion:

Manufacturing Facility Investment: The largest allocation of ₹107.00 crore for investment in subsidiary Havix to establish a sterile injections manufacturing facility in Atlanta shows ₹6.98 crore utilized, with ₹100.02 crore remaining for the ongoing project.

Debt Repayment Objectives: Two debt repayment objectives totaling ₹93.30 crore have been fully completed. The company successfully repaid ₹73.10 crore of its own borrowings and ₹20.20 crore of subsidiary borrowings, both completed in Q1FY26.

Working Capital Requirements: For funding working capital needs, ₹43.26 crore was allocated to the company itself, with ₹42.21 crore utilized, leaving ₹1.05 crore unutilized. An additional ₹59.48 crore was designated for subsidiaries SPI and Ratnatris, with ₹56.88 crore deployed and ₹2.60 crore remaining.

Strategic Initiatives and General Corporate Purposes

The company allocated ₹154.77 crore for inorganic growth, acquisitions, and general corporate purposes, utilizing ₹128.53 crore with ₹26.23 crore remaining. The monitoring agency noted that ₹61.32 crore was used for general corporate purposes, while ₹67.21 crore supported strategic initiatives.

Implementation Delays and Compliance

The monitoring agency reported minor delays in two objectives that were originally scheduled for completion by March 2025 but were completed in Q1FY26:

• Subsidiary borrowing repayment: Delayed by 25 days due to bank negotiations to avoid prepayment penalties
• Subsidiary working capital funding: Delayed by 43 days based on subsidiary requirements

Both delays were approved by the management committee with a three-month extension granted on March 27, 2025.

Deployment of Unutilized Funds

The unutilized amount of ₹137.88 crore has been strategically deployed in fixed deposits and bank accounts to generate returns:

The total earnings from these investments amount to ₹8.23 crore as accrued interest, bringing the total value to ₹146.11 crore as of December 31, 2025.

Regulatory Compliance and Monitoring

CARE Ratings Limited, serving as the monitoring agency, confirmed no material deviations from the original offer document objectives. All government and statutory approvals related to the objectives have been obtained where applicable. The report emphasizes that the company maintains flexibility in fund utilization as outlined in the original offer document, subject to regulatory compliance.

The monitoring agency noted that funds transferred to foreign bank accounts resulted in comingling, requiring reliance on management declarations and chartered accountant certificates to ascertain proper utilization. The report maintains that all utilizations align with the disclosed objectives in the offer document.

*Source: *

Senores Pharmaceuticals has reported impressive financial results for the third quarter, with consolidated net profit showing substantial year-on-year growth. The pharmaceutical company's strong performance demonstrates its operational capabilities and market positioning.

Financial Performance Overview

The company's third quarter consolidated results show remarkable improvement in profitability metrics. The net profit growth of 86% year-on-year indicates strong operational performance and effective business execution during the quarter.

Business Performance Analysis

The significant increase in consolidated net profit from ₹170.00 million to ₹317.00 million represents a substantial improvement in the company's financial health. This growth trajectory reflects the pharmaceutical company's ability to enhance its operational efficiency and market reach.

The year-on-year comparison demonstrates consistent business momentum, with the company successfully expanding its profitability base. The 86% growth rate indicates strong underlying business fundamentals and effective strategic execution.

Market Position

Senores Pharmaceuticals' robust third quarter performance positions the company favorably within the pharmaceutical sector. The substantial profit growth suggests effective cost management and revenue optimization strategies implemented by the management team.

The consolidated results reflect the overall performance across the company's business segments, indicating broad-based operational improvements. This financial achievement demonstrates the company's commitment to delivering value to stakeholders while maintaining operational excellence in the competitive pharmaceutical market.